ArticleBMJ case reports2012
Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.
Article in BMJ case reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- A network pharmacology-guided multi-omics and spatial single-cell framework nominates WT1 as a spironolactone-linked immune biomarker in prostate cancer.Frontiers in pharmacology · 2026Article
- Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.Acta Cardiologica Sinica · 2025Article
- Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective Study.The Prostate · 2025Article
- Management of hypertension in patients with cancer: challenges and considerations.Clinical kidney journal · 2023Review
- Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.BMJ case reports · 2022Article
- Cardiometabolic Comorbidities in Cancer Survivors:JACC. CardioOncology · 2022Review
- Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.Clinical hypertension · 2022Review
- The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.Frontiers in oncology · 2021Review
- Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis.Clinical hypertension · 2019Article
- Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis.Clinical hypertension · 2019Article
- Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.Endocrine connections · 2017Review
- Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.British journal of clinical pharmacology · 2017Article
- Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.Journal of endocrinological investigation · 2016Article
- Sexual Reassignment Fails to Prevent Kennedy's Disease.Journal of neuromuscular diseases · 2016Article
- Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Nature reviews. Urology · 2015Review
- Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors report the case of an 80-year-old man who had heavily pretreated castration refractory carcinoma of the prostate and heart failure. Following the introduction of spironolactone to manage his heart failure, the patient experienced clinical and biochemical progression of his prostate cancer. Within 2 weeks of withdrawing spironolactone the patient's prostate-specific antigen returned its previous level. This is the first reported case of clinical and biochemical progression of prostate cancer following the introduction of spironolactone. The authors propose that spironolactone is a selective androgen receptor modulator. Spironolactone should be used in caution with men with prostate cancer, and should not be used to treat oedema, hypokalaemia and hypertension associated with the newly licensed hormonal therapy abiraterone acetate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.